OncoMatch/Clinical Trials/NCT06888817
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Is NCT06888817 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Dexamethasone for radiation necrosis.
Treatment: Bevacizumab · Dexamethasone — Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality of life (QoL). The first-line therapy for symptomatic CRN (sCRN) is corticosteroids, primarily dexamethasone, which often leads to complications, refractory symptoms, and interference with anti-cancer treatment. Since 2017, bevacizumab, an antibody against Vascular Endothelial Growth Factor (VEGF), has been used in a second-line treatment setting for refractory sCRN. A small randomized clinical trial (RCT) has shown that bevacizumab significantly diminishes cerebral edema on MRI and decreases clinical symptoms of sCRN in irradiated glioma patients. Several non-randomized clinical studies demonstrated a beneficial radiological and clinical effect of bevacizumab in patients with sCRN after irradiation for BM. The optimal first-line treatment for sCRN is currently unknown. Effective and safe first-line treatment of sCRN will optimize the patient's well-being and health-related QoL. Furthermore, minimizing corticosteroid use will benefit the clinical treatment options and outcomes of concomitant or future anti-cancer treatment. This phase III multicenter, open-label, randomized clinical trial compares the clinical efficacy of first-line bevacizumab versus standard-of-care dexamethasone for sCRN in patients with high-grade glioma (HGG) or BM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Glioblastoma
Performance status
KPS 0–90
Prior therapy
Must have received: focal (re-)irradiation
First episode of sCRN ≥ 3 months after completion of focal (re-)irradiation
Cannot have received: bevacizumab (bevacizumab)
Exception: allowed if >6 months before diagnosis of sCRN
Prior treatment with bevacizumab <6 months before diagnosis of sCRN
Cannot have received: high dose radiotherapy in the abdomen
Previous, current or planned high dose radiotherapy in the abdomen
Lab requirements
Blood counts
Decreased platelet count < 75x10^9/L
Kidney function
Calculated (Cockcroft-Gault) or measured creatinine clearance <30 mL/min; urine dipstick for proteinuria ≥ 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein/24 hr.
Cardiac function
Clinical significant cardiovascular disease (see exclusion criteria for details)
Nephrotic syndrome or abnormal renal function; Calculated (Cockcroft-Gault) or measured creatinine clearance <30 mL/min; urine dipstick for proteinuria ≥ 2+. Decreased platelet count < 75x10^9/L. Clinical significant cardiovascular disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06888817 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bevacizumab, high dose radiotherapy in the abdomen disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages